AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12077585
Drug: Systemic antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antifungal (terbinafine)
Trial: 12077585
Drug: Systemic antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antifungal (itraconazole)
Trial: 2668427
Drug: Cefotaxime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (2 g every 6 h)
Trial: 327944
Drug: Intramuscular salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular salbutamol 20 microgram/kg
Trial: 31769299
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (group cognitive rehabilitation programme delivered in 10 weekly sessions)
Trial: 30561849
Drug: Prednisolone and
RxNorm normalized name: prednisolone and mydriatics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone and oral vitamin D (n=15)
Trial: 28547999
Drug: Handwriting intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Handwriting intervention (self-managed at home, 1 hour, twice weekly for 6 months)
Trial: 28399988
Drug: Y-SBNT (adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y-SBNT (adapted youth social behaviour and network therapy)
Trial: 24868255
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fat graft, laser CO2, and platelet-rich plasma (PRP)
Trial: 18979616
Drug: Yoghurt containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt containing 1 g plant sterols (Study I)
Trial: 18979616
Drug: Yoghurt containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoghurt containing 2 g plant sterols (Study II)
Trial: 16610925
Drug: Recycling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recycling intervention strategy to increase tobacco dependence treatment rates
Trial: 12394419
Drug: Alprazolam (0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25, 0.50, 0.75 mg)
Trial: 1487624
Drug: Alprazolam (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.75 mg)
Trial: 12394419
Drug: Buspirone (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (5, 10, 15 mg)
Trial: 6499355
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 to 480 mg%)
Trial: 6499355
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 to 360 mg%)
Trial: 6499355
Drug: Verapamil (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (480 mg%)
Trial: 10390389
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 micrograms twice daily (FP200)
Trial: 10390389
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 micrograms twice daily (FP100)
Trial: 8219927
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of acetaminophen
Trial: 8219927
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acetaminophen)
Trial: 3691593
Drug: Nisoldipine 5
RxNorm normalized name: nisoldipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 5 mg daily
Trial: 15162946
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (Beclomethasone) plus prolonged action bronchodilator (Salmeterol)
Trial: 15162946
Drug: Inhaled steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroids (Beclomethasone)
Trial: 11458057
Drug: Polyestradiol phosphate
RxNorm normalized name: POLYESTRADIOL PHOSPHATE
DrugBank: Polyestradiol phosphate (DB09369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polyestradiol phosphate (240 mg intramuscular injections every 2 weeks for 8 weeks, then monthly)
Trial: 11458057
Drug: Complete androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete androgen ablation (bilateral orchiectomy or 3.75 mg triptorelin monthly with 250 mg flutamide 3 times daily)
Trial: 10089183
Drug: Warfarin (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted to achieve an INR of 2.0 to 3.0)
Trial: 1100014
Drug: 5,000 international
RxNorm normalized name: Nature Made Beta Carotene 25,000 International Units Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 international units aqueous heparin sodium
Trial: 21628010
Drug: Various endoscopic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various endoscopic technologies (e.g., colonoscopy, third eye retroscope, cap-fitted, cap-assisted)
Trial: 18993031
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to other medications from olanzapine
Trial: 18993031
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to other medications from risperidone
Trial: 16550824
Drug: Prostamol Uno
RxNorm normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostamol Uno 320 mg
Trial: 12856138
Drug: Controlled ileal-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled ileal-release budesonide (9 mg by mouth)
Trial: 7687421
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with hyperthermia (HCR)
Trial: 7687421
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Group A)
Trial: 22532945
Drug: Breezy candy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breezy candy (sugar-free) containing zinc gluconate 0.5%, propolis 2%, and a combination of both (zinc 0.25% and propolis 1%)
Trial: 31483938
Drug: Tinnitus Multivariate
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinnitus Multivariate Integrated Sound Therapy (T-MIST)
Trial: 26498242
Drug: Rilmazafone 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmazafone 1 mg
Trial: 21864613
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator (licensed Td vaccine)
Trial: 9400950
Drug: CDDP/VNR (Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP/VNR (Cisplatin 100 mg m-2 on day 1 + Vinorelbine 25 mg m-2 i.v. on days 1 and 8 every 21 days for three cycles)
Trial: 9400950
Drug: IFO/EPI (Ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFO/EPI (Ifosfamide 2.5 g m-2 with mesna on day 1 + High-dose Epirubicin 100 mg m-2 on day 1 every 21 days for three cycles)
Trial: 8423870
Drug: Intranasal DGAVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal DGAVP treatment
Trial: 2881482
Drug: Soy polysaccharide
RxNorm normalized name: Soy polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy polysaccharide (10 g)
Trial: 24093504
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (200/25 μg)
Trial: 24093504
Drug: Fluticasone furoate/vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate/vilanterol (800/100 μg)
Trial: 23084328
Drug: Minor drug
RxNorm normalized name: Vinca minor extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minor drug onset sensations
Trial: 8907095
Drug: Group behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavioral treatment
Trial: 8907095
Drug: Minimal contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal contact plus 2 mg of nicotine gum
Trial: 6136395
Drug: Sulfasalazine (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (2.0 g/day)
Trial: 30639089
Drug: Postoperative bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative bladder backfilling with 150 mL of normal saline
Trial: 26156227
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue (2 ml Tissucol®; Duploject, Baxter AG) applied on surgical wound before closure
Trial: 23870813
Drug: Discontinuous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuous treatment
Trial: 12908891
Drug: Increased ALNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased ALNA intake (10 g/d, n 4)
Trial: 12908891
Drug: Increased EPA+DHA
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased EPA+DHA intake (1.5 g/d, n 5)
Trial: 1875415
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 doxorubicin
Trial: 1875415
Drug: 320 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg/m2 bisantrene
Trial: 1875415
Drug: 14 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg/m2 mitoxantrone
Trial: 6871069
Drug: Terbutaline sulphate
RxNorm normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline sulphate (1 mg)
Trial: 18715665
Drug: Interferon alfa-based
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-based antiviral therapies or treatment with polymerase inhibitors
Trial: 18715665
Drug: Initial viral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR)
Trial: 14669615
Drug: prestarium (2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prestarium (2‐4 mg/day)
Trial: 14669615
Drug: standard combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard combined therapy
Trial: 11071181
Drug: suplatast tosilate
RxNorm normalized name: Edoxaban Tosylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suplatast tosilate (100 mg three times daily)
Trial: 9011485
Drug: Levothyroxine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (1.5 micrograms/kg daily)
Trial: 9011485
Drug: Iodine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine (300 micrograms daily)
Trial: 1735253
Drug: Budesonide 600
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 600 micrograms twice daily
Trial: 6321684
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMZ) 320/1600 mg/day
Trial: 30396226
Drug: Routine aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine aspirin 75 mg
Trial: 30571234
Drug: Fetal Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetal Medicine Foundation screen-and-treat approach
Trial: 24102322
Drug: Sumatriptan 85
RxNorm normalized name: sumatriptan 85 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 85 mg/Naproxen sodium 500 mg (S/NS)
Trial: 22318095
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg a day for 2 years
Trial: 11720459
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and best supportive care (BSC)
Trial: 8083129
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation (single 7-8 Gy fraction administered < 4 h before surgery)
Trial: 8083129
Drug: Postoperative irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative irradiation (single 7-8 Gy fraction administered < 48 h after surgery)
Trial: 2521644
Drug: imipramine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imipramine 200 mg/day for 3 weeks
Trial: 1147583
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g every 6 h for 48 h
Trial: 1147583
Drug: Cephalothin 2
RxNorm normalized name: cephalothin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalothin 2 g every 6 h for 48 h
Trial: 15174779
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (supplement without zinc)
Trial: 2929526
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral obesity treatment
Trial: 30903287
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol 200 μg
Trial: 30903287
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol 100 μg
Trial: 30073445
Drug: Mobile app
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile app for drug administration
Trial: 28363526
Drug: Ceftazidime/avibactam (2000/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime/avibactam (2000/500 mg, 2-h infusion) plus metronidazole (500 mg, 60-min infusion)
Trial: 28363526
Drug: Meropenem (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1000 mg, 30-min infusion)
Trial: 21718775
Drug: Portulaca oleracea
RxNorm normalized name: Portulaca Oleracea Top
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Portulaca oleracea (PO) seeds, 5 g twice daily
Trial: 21718775
Drug: Metformin, 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 1,500 mg/day
Trial: 18640386
Drug: Oral ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ERT
Trial: 18640386
Drug: Transdermal ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal ERT
Trial: 16595206
Drug: DMPA-SC (104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMPA-SC (104 mg)
Trial: 16595206
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (11.25 mg)
Trial: 12874697
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg intravenous infusion)
Trial: 9428817
Drug: Daclizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1.0 mg/kg body weight, administered intravenously before transplantation and once every other week afterward for a total of five doses)
Trial: 9428817
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered intravenously before transplantation and once every other week afterward for a total of five doses)
Trial: 2501243
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus mitomycin C
Trial: 831472
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Trial: 831472
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of heparin 1,000 units to each liter of intravenous fluid
Trial: 831472
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of heparin 500 units and hydrocortisone phosphate 1 mg to each liter of intravenous fluid
Trial: 831472
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of heparin 1,000 units and hydrocortisone phosphate 10 mg to each liter of intravenous fluid
Trial: 831472
Drug: Filtration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filtration of intravenous solutions through a 0.22‐mum inline filter
Trial: 31694152
Drug: Mixed flavonoid-caffeine
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed flavonoid-caffeine (MFC) supplement (658 mg flavonoids, 214 mg caffeine)
Trial: 31694152
Drug: Mixed flavonoid-caffeine
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed flavonoid-caffeine (MFC) supplement
Trial: 25936297
Drug: 0.1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g/kg l‐methionine to induce hyperhomocysteinemia
Trial: 25936297
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml whipping cream (30% fat) to induce hyperlipidemia
Trial: 18800037
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil administered for up to 7 days
Trial: 16490627
Drug: Ramipril, 2.5
RxNorm normalized name: Ramipril, 2.5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril, 2.5 mg 3 times/wk
Trial: 15256981
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment followed by Helicobacter pylori test and treat strategy (treat and test group)
Trial: 8342399
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (4 micrograms/kg loading dose followed by 1 microgram/kg/h infusion)
Trial: 27639819
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) 0.5 mg/kg, twice daily (max 60 mg/day) from day one until discharge
Trial: 20214176
Drug: Topical hemostatic
RxNorm normalized name: ferric sulfate 21 % Topical Hemostatic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical hemostatic powder (THP)
Trial: 12496983
Drug: Periprostatic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic injection of 5 ml 1% lidocaine solution (2.5 ml bilaterally)
Trial: 9156938
Drug: HIV-negative drug
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-negative drug addicts (1986-87)
Trial: 9156938
Drug: HIV-positive drug
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-positive drug addicts
Trial: 1859008
Drug: Propofol 2
RxNorm normalized name: propofol 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2 mg.kg‐1 bolus followed by infusion of 160 microgram.kg‐1.min‐1
Trial: 6344981
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and high-dose methotrexate
Trial: 28925135
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii glycosides (20 mg, tid for 4 weeks, then 10 mg, tid) combined with gestrinone (2.5 mg on 1st and 4th day of menstrual cycle, then twice a week)
Trial: 28925135
Drug: Gestrinone capsule
RxNorm normalized name: gestrinone
DrugBank: Gestrinone (DB11619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone capsule (same intake method as treatment group)
Trial: 9492127
Drug: Injection within
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection within the wound (0.5 mL buffered lidocaine)
Trial: 9492127
Drug: Injection through
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection through intact skin (0.5 mL buffered lidocaine)
Trial: 9492127
Drug: First injection
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First injection (within wound) in group 1
Trial: 9492127
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection (intact skin) in group 1
Trial: 9492127
Drug: First injection
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First injection (intact skin) in group 2
Trial: 9492127
Drug: Second injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second injection (within wound) in group 2
Trial: 8113006
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol (0.25%)
Trial: 3381775
Drug: Half-strength formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength formula (equal parts, 84 J/30 mL [20 cal/oz] formula and water)
Trial: 3381775
Drug: Full-strength (FS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength (FS) formula (84 J/30 mL [20 cal/oz])